Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
BLPH
$3.25
Bellerophon Ther Com
($.12)
(3.56%)
BLPH
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus: ($0.56)
Revenue: $0.00 Mil
Monday
Feb 14
8:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Monday, November 15, 2021
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
What do you expect when BLPH reports earnings?
Beat
Meet
Miss
Where is BLPH's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey.
Peers
Vertex Pharmaceuticals
Ultragenyx Pharmaceutical
Regeneron Pharmaceuticals
BioMarin Pharmaceutical
Merck & Co.
Zoetis
Eli Lilly
Bristol-Myers Squibb
Pfizer
InterCept
Expectations
›
Bellerophon Ther Com
